Journal
CNS SPECTRUMS
Volume 13, Issue 6, Pages 511-514Publisher
M B L COMMUNICATIONS, INC
DOI: 10.1017/S1092852900016746
Keywords
-
Categories
Ask authors/readers for more resources
Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available